|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
InSite Vision
| | | Phone: | (510) 865-8800 | Fax: | (510) 865-5700 | Year Established: | 1986 | Ticker: | ISV | Exchange: | AMEX | Main Contact: | Lyle M. Bowman, Ph.D., VP, Development | | Other Contacts: | Surendra Patel, VP, Operations Kamran Hosseini, M.D., Ph.D., CMO
| | Company Description | InSite Vision, a SUN PHARMA company is an ophthalmic company primarily focused on developing therapies that treat ocular infection and inflammation, glaucoma, and retinal diseases.
InSIte Vision, Sun Pharma?s wholly-owned subsidiary has received approval from US FDA on April 8th, 2016 for its New Drug Application (NDA) related to BromSite (bromfenac ophthalmic solution) 0.075 per cent for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. BromSite is the first non-steroidal anti-inflammatory drug (NSAID) approved by the US FDA to prevent pain and treat inflammation in the eye for patients undergoing cataract surgery. /p> | |
|
|
|
|
|